This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...

This week’s update looks at a combined vaccine/CRISPR-edited T cell trial for prostate cancer, and a CRISPR-edited CAR-T cell trial for non-small cell...